Werewolf announces initial trial results evaluating INDUKINE for lymphoma

Werewolf Therapeutics announced initial results from the Phase 1 clinical trial evaluating WTX-330, its conditionally activated interleukin-12 or IL-12, INDUKINE molecule, as monotherapy in patients with immunotherapy insensitive or resistant locally advanced or metastatic solid tumors or non-Hodgkin lymphoma. “Our focus at Werewolf is grounded in advancing a pipeline of next generation, transformative immuno-stimulatory medicines,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “These preliminary clinical data show promising tolerability and signals of efficacy of WTX-330 in heavily pretreated patients with late-stage solid tumors. We look forward to continued advancement of WTX-330 and further understanding the potential clinical benefit for this molecule.” IL-12 therapy holds tremendous promise for immune-resistant cancer patients but has been historically limited by severe toxicity, like many cytokines. Werewolf is developing a novel, conditionally activated IL-12, WTX-330, in order to overcome this key limitation with its systemically administered, tissue-targeted technology, optimizing its therapeutic index so that efficacious doses can be delivered for clinical impact.